Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
IBM director Frank Baker files initial beneficial ownership statement

IBM director Frank Baker files initial beneficial ownership statement

BitgetBitget2026/10/08 21:09

IBM director Frank Baker filed an initial Form 3 beneficial ownership statement dated Oct. 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IBM - International Business Machines Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001441756-26-000003), on October 08, 2026, and is solely responsible for the information contained therein.

  • IBM director Frank Baker filed an initial Form 3 beneficial ownership statement dated Oct. 1, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IBM - International Business Machines Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001441756-26-000003), on October 08, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.

Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.

智通财经•2026/10/09 07:09

Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.

Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.

智通财经•2026/10/09 07:08

Pimco warns: 10-year US Treasury yield may hit 6%, for the first time since 2000

PIMCO's Chief Investment Officer stated that due to high oil prices intensifying inflation concerns and market unease over the growing U.S. public debt, the benchmark 10-year U.S. Treasury yield could rise to 6% for the first time since 2000.

智通财经•2026/10/09 06:47